Does Dr. MARK COVINGTON have financial conflicts of interest?

Dr. MARK COVINGTON (M.D.) has received a total of $1,535 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,535 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MARK COVINGTON?

According to CMS Open Payments data, Dr. MARK COVINGTON received funding from REGENERON HEALTHCARE SOLUTIONS ($499), GLAXOSMITHKLINE ($258), and GENZYME CORPORATION ($221).

Does Dr. MARK COVINGTON receive research grants or speaking fees?

Dr. MARK COVINGTON has received $1,535 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MARK COVINGTON

M.D.Real-Time Hydrated

Specialty: Otolaryngology

Practice Location: LEES SUMMIT, MO 64064

NPI Number: 1740201599

LIFETIME INDUSTRY VALUE

$1,535

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. COVINGTON is a verified Otolaryngology practitioner based in LEES SUMMIT, MO.

Between 2021 and 2024, Dr. COVINGTON had an overall industry promotional and research financial footprint of $1,535 as recorded in the federal CMS Open Payments database.

$1,535 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. COVINGTON's primary funding source is REGENERON HEALTHCARE SOLUTIONS, which accounts for $499 (representing 32.5% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON HEALTHCARE SOLUTIONS

Rank 1

$499

32.5%

GLAXOSMITHKLINE

Rank 2

$258

16.8%

GENZYME CORPORATION

Rank 3

$221

14.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.